| Document |
Document Title |
|
WO/2022/074068A1 |
The present invention describes disorazoles and their analogues as described in formula III wherein the variables are defined in the description, or pharmaceutically acceptable salts thereof. Described is also a novel synthetic pathway f...
|
|
WO/2022/075486A1 |
A compound of the formula (I): wherein each symbol is as defined in the DESCRIPTION, or a pharmaceutically acceptable salt thereof has a superior Notch signal transduction inhibitory action, and is useful for preventing or treating vario...
|
|
WO/2022/070287A1 |
Provided is a compound represented by general formula (1) or a salt thereof, the compound or the salt thereof having excellent IRAK-4 inhibitory activity and being useful as an active ingredient of a drug for preventing and/or treating a...
|
|
WO/2022/070289A1 |
This compound, or salt thereof, is represented by general formula (1), exhibits excellent IRAK-4 inhibitory activity and is useful as an active ingredient of a medicine for preventing and/or treating a disease which pertains to IRAK-4 in...
|
|
WO/2022/063016A1 |
The present invention relates to a deuterated dihydrodibenzothiepine compound, a tautomer, stereoisomer, prodrug, pharmaceutically acceptable salt, hydrate, or solvate thereof, a pharmaceutical composition containing the compound, and a ...
|
|
WO/2022/063333A1 |
Disclosed are a pyrimidine carboxamide compound and an application thereof. Further provided are a pyrimidine carboxamide compound represented by formula (I), or a tautomer, mesomer, racemate, enantiomer, or diastereomer thereof, a mixtu...
|
|
WO/2022/063190A1 |
A pyrazine thiobiphenyl compound and an application thereof, and specifically disclosed is a compound represented by formula (II) or a pharmaceutically acceptable salt thereof.
|
|
WO/2022/066917A1 |
Disclosed are compounds of Formula (1) and pharmaceutically acceptable salts thereof, wherein L1, R1, R2, R3, R4, R6, R7, R8, R9 and X5 are defined in the specification. This disclosure also relates to materials and methods for preparing...
|
|
WO/2022/063299A1 |
The present invention relates to a 1,2,4-triazolone derivative serving as a DHODH inhibitor. The present invention specifically relates to a compound shown by general formula (1) and a preparation method therefor, and an application of t...
|
|
WO/2022/058877A1 |
The present invention relates to a compound of formula (I), Formula (I) wherein, R1, R1a, R2, W, R3, R4, R5, and Z are as defined in the detailed description and to a process for preparing the compound of formula (I). The present inventi...
|
|
WO/2022/060951A1 |
Described herein are small molecule splicing modulator compounds that modulate splicing of mRNA, such as pre-mRNA, encoded by genes, and methods of use of the small molecule splicing modulator compounds for modulating splicing and treati...
|
|
WO/2022/060973A1 |
Described herein are compounds of Formula (I) that are useful in treating a TYK2-mediated disorder. In some embodiments, the TYK2-mediated disorder is an autoimmune disorder, an inflammatory disorder, a proliferative disorder, an endocri...
|
|
WO/2022/060943A1 |
Described herein are small molecule splicing modulator compounds that modulate splicing of mRNA, such as pre-mRNA, encoded by genes, and methods of use of the small molecule splicing modulator compounds for modulating splicing and treati...
|
|
WO/2022/058878A1 |
The present invention relates to a compound of formula (I), Formula (I), wherein, R1, R1a, R2, W, R3, R4, R5, A, R6, R7 and R8 are as defined in the detailed description and to a process for preparing the compound of formula (I). The pre...
|
|
WO/2022/061251A1 |
Disclosed are compounds of Formula I: or a pharmaceutically acceptable salt, a solvate, a tautomer, a stereoisomer, or a deuterated analog thereof, wherein: R1, R2, R3, X, and Z are as described in any of the embodiments described in thi...
|
|
WO/2022/058920A1 |
A compound of Formula (I), pharmaceutical compositions containing them, methods of making them, and methods of using them including methods for treating disease states, disorders, and conditions associated with casein kinase 1 delta (CSN...
|
|
WO/2022/052925A1 |
Provided is a new crystal form of (7S,13R)-11fluoro-7,14-dimethyl-6,7,13,14-tetrahydro-1,15-vi
nyl-bridged pyrazolo[4,3-f][1,4,8,10]-benzoxatriazacyclotridecyne-4(5H)-
one (formula I). In another aspect, provided is a method for preparin...
|
|
WO/2022/055168A1 |
The present invention relates to a pyrimidodiazepine derivative or a pharmaceutically acceptable salt thereof and a use thereof. A pyrimidodiazepine derivative or a pharmaceutically acceptable salt thereof according to the present invent...
|
|
WO/2022/054005A1 |
Novel compounds having formula (I) and methods of using these compounds to treat diseases, conditions, and disorders are described.
|
|
WO/2022/052958A1 |
This disclosure relates to GLP-1 agonists of Formula (I), including pharmaceutically acceptable salts and solvates thereof, and pharmaceutical compositions including the same.
|
|
WO/2022/056092A1 |
Provided herein are methods of preventing and treating viral infections (e.g., coronavirus infection) using a compound of Formula (I).
|
|
WO/2022/054083A1 |
The present invention relates to a synergistic insecticidal composition comprising Acetamiprid, Flonicamid and Pyriproxyfen, process of preparation of composition and uses thereof.
|
|
WO/2022/051583A1 |
The present disclosure relates to compounds of Formula (I') and to their prodrugs, pharmaceutically acceptable salts, pharmaceutical compositions, methods of use, and methods for their preparation. The compounds disclosed herein are usef...
|
|
WO/2022/049005A1 |
The present invention relates to high affinity macrocyclic FKB51-Inhibitors (HAM-FKB51-Inhibitors), which enable the selective inhibition of FK506-binding proteins (FKBPs). The molecules of the present invention are useful for the treatm...
|
|
WO/2022/043491A2 |
Disclosed herein are detectable moieties and detectable conjugates comprising one or more detectable moieties. In some embodiments, the disclosed detectable moieties have a narrow wavelength and are suitable for multiplexing. Also disclo...
|
|
WO/2022/041615A1 |
The present invention relates to the field of pesticides, and specifically relates to a substituted phenylpyrazoline derivative or a salt thereof as a pesticide, and a composition and use thereof. The compound has the structure of formul...
|
|
WO/2022/040469A1 |
Compounds according to Formula 1 are capable of inhibiting a RAS protein form.
|
|
WO/2022/034616A1 |
Described herein is a method for treating and/or preventing a disease or disorder or condition associated with NETosis, the method comprising: administering to a subject a compound as disclosed herein, or its polymorph, stereoisomer, pro...
|
|
WO/2022/034529A1 |
The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof; (I) wherein R1 R2, R4 and X1 are defeined herein, a method for manufacturing the compounds of the invention, and its therapeutic uses...
|
|
WO/2022/029096A1 |
The present invention relates to compounds which are suitable for use in electronic devices, and to electronic devices, in particular organic electroluminescent devices, containing said compounds.
|
|
WO/2022/029170A1 |
The present invention relates to difluoromethyl-pyridin-2-yl triazoles of general formula (I) which are modulators of GABAA receptors containing the α5 subunit, useful in treating central nervous system diseases and other diseases. In a...
|
|
WO/2022/029068A1 |
The present invention relates to compounds of formula (I), (I), wherein R1, R2, R3, R4 and A are as described herein, and their pharmaceutically acceptable salt thereof, and compositions including the compounds and methods of using the c...
|
|
WO/2022/026500A1 |
Disclosed are compounds of Formula 1, all stereoisomers, N-oxides and salts thereof, wherein G is CONR5R6 or selected from and R1 through R18 Rf and G are as defined in the Disclosure. Also disclosed are compositions containing the compo...
|
|
WO/2022/023772A1 |
The present invention relates to compounds of formula (I) shown below: wherein R1, R2, R3, R4, R5 and R6 are each as defined in the application. The present invention also relates to processes for the preparation of these compounds, to p...
|
|
WO/2022/022664A1 |
Disclosed is a type of indolo heptamyl oxime analog crystal as a PARP inhibitor and a method for preparing the same, specifically relating to a crystal of a compound as represented by formula (I) and a method for preparing the same.
|
|
WO/2022/026892A1 |
Compounds are provided according to Formula (I) and pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof; wherein R1, R2, R3, R4, R6, R7, R8 and n are as defined herein. Compounds of the present invention ar...
|
|
WO/2021/249913A9 |
The present invention relates to Map4K1 inhibitors of formula (I), to pharmaceutical compositions and combinations comprising the compounds according to the invention, and to the prophylactic and therapeutic use of the inventive compound...
|
|
WO/2022/022846A1 |
The present invention relates to a compound of general formula (I) wherein R1-7, Hy, and X are as defined in claim 1. Such compound of formula (I) binds to VDAC1 and is suitable for use in a method for treating diabetes or pre- diabetes ...
|
|
WO/2022/026863A2 |
This disclosure relates to compounds that are cystic fibrosis transmembrane conductance regulator (CFTR) modulators and pharmaceutical compositions containing the same. In certain embodiments, this disclosure relates to methods of managi...
|
|
WO/2022/020247A1 |
Disclosed are compounds, compositions, and methods useful for treating or preventing a disease or disorder associated with mutation in a protein.
|
|
WO/2022/020342A1 |
Provided herein are compounds of formula (V) that bind to BF3 of an androgen receptor (AR), which can modulate the AR for the treatment of Kennedy's disease.
|
|
WO/2022/020522A2 |
The disclosure provides compounds and salts that show high selectivity and inhibitory activity for mTORC1 and uses thereof for the treatment of disease.
|
|
WO/2022/012593A1 |
A compound represented by general formula (1), a preparation method therefor, and a use of the compound represented by general formula (1), an isomer thereof, a crystal form thereof, a pharmaceutically acceptable salt thereof, a hydrate ...
|
|
WO/2022/014724A1 |
A compound of the formula (I): wherein each symbol is as defined in the DESCRIPTION, or a pharmaceutically acceptable salt thereof has a superior inhibitory activity on cancer cell proliferation.
|
|
WO/2022/013312A1 |
The present invention relates to a compound of general formula (I) inhibiting the transforming growth factor-β (TGF-β) type I receptor (ALK5), methods of preparing such compounds, pharmaceutical compositions containing them and therape...
|
|
WO/2022/015938A1 |
This disclosure features chemical entities (e.g., a compound or a pharmaceutically acceptable salt, and/or hydrate, and/or cocrystal, and/or drug combination of the compound) that inhibit (e.g., antagonize) Stimulator of Interferon Genes...
|
|
WO/2022/013311A1 |
PYRIDO OXAZINE DERIVATIVES AS ALK5 INHIBITORS The present invention relates to a compound of general formula (I) inhibiting the transforming growth factor-β (TGF-β) type I receptor (ALK5), methods of preparing such compounds, pharmaceu...
|
|
WO/2022/008912A1 |
Benzodiazepine derivatives of formula (lb) wherein: R1 is H or halo; Y is selected from O, S, SO, SO2 and NR; one or two of V, W and X is or are N or CH and the other one or two is or are CH; R2 is a group selected from C1-C6 alkyl, C1-C...
|
|
WO/2022/007810A1 |
A tricyclic pyrimidinone compound as represented by formula (I) or a pharmaceutically acceptable salt thereof, wherein the compound has a structure as represented by formula (I), is a completely new Lp-PLA2 inhibitor, and can be used for...
|
|
WO/2022/011204A1 |
The present disclosure provides compounds represented by Formula I: A-L-B1 I, and the salts or solvates thereof, wherein A, L, and B1 are as defined in the specification. Compounds having Formula I are androgen receptor degraders useful ...
|
